AbbVie v. Hetero USA: 39-Patent RINVOQ Consent Injunction (400 Days)
AbbVie filed suit in the Delaware District Court asserting 39 patents covering its JAK1 inhibitor RINVOQ (upadacitinib) against Hetero’s ANDA for generic extended-release tablets. Hetero admitted that all 39 patents are valid, enforceable, and infringed — securing AbbVie a court-ordered injunction blocking generic entry for the life of every asserted patent.
AbbVie locks RINVOQ against Hetero with sweeping consent injunction
On 8 August 2024, AbbVie, Inc. filed a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware before Judge Maryellen Noreika, asserting 39 patents against Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hoster Labs Private Limited in connection with ANDA No. 218859 — Hetero’s application to market generic upadacitinib extended-release tablets in 15 mg, 30 mg, and 45 mg strengths, the same doses marketed under AbbVie’s RINVOQ brand.
The case resolved on 12 September 2025 — 400 days after filing — when the court entered a stipulated order in which the Hetero defendants expressly admitted that all 39 asserted patents are valid, enforceable, and would be infringed by commercial manufacture, sale, or importation of the ANDA products. The court permanently enjoined Hetero from marketing or selling those generic products in the United States for the full life of the patents, including any term extensions and pediatric exclusivities, absent an AbbVie licence.
A 400-day resolution is notably swift for a case spanning 39 patents, suggesting Hetero concluded early that the patent portfolio was too broad to challenge cost-effectively. The public record does not disclose whether a confidential licence or settlement agreement exists alongside the stipulated order; the order expressly preserves AbbVie’s ability to enforce the same patents against Hetero for products other than the ANDA 218859 formulation, which is consistent with a structured resolution rather than a pure capitulation.
Filing to Case Dismissed in 400 days
400-day resolution — faster than the typical ANDA Hatch-Waxman trial lifecycle
Consent injunction entered: what the stipulated order means for both parties
Hetero admitted infringement — no trial, direct consent order
Under 35 U.S.C. § 271(e)(2)(A), filing an ANDA constitutes an act of infringement. Hetero’s stipulation expressly admits both that act and that commercial sale would infringe all 39 patents. The court converted that admission into a permanent injunction by consent order — a binding judicial decree that survives any personnel change at Hetero and is enforceable by contempt, without requiring AbbVie to re-litigate validity or infringement.
Consent permanent injunctionAbbVie secures lifecycle protection across all 39 RINVOQ patents
The injunction blocks Hetero from launching any generic upadacitinib ER tablet covered by ANDA 218859 for the entire remaining life of 39 patents, including term extensions and pediatric exclusivity. Critically, Hetero expressly waived its right to appeal, giving AbbVie certainty. The order also reserves AbbVie’s rights against Hetero for any future ANDA covering a different upadacitinib product — preserving offensive optionality across the full RINVOQ lifecycle.
Full-portfolio injunction securedHetero blocked from RINVOQ market; validity challenge door remains open on other products
Hetero is permanently enjoined from commercialising the ANDA 218859 products absent a licence. By admitting validity and infringement of all 39 patents, Hetero forecloses any near-term re-entry argument for this specific formulation. However, the order is explicitly without prejudice to future actions involving a different product — meaning Hetero retains the ability to file a new ANDA for a distinct upadacitinib formulation and challenge the patents afresh, a strategically important carve-out.
ANDA 218859 permanently blocked39-patent fortress reinforced — high bar for all RINVOQ generic challengers
A stipulated admission that 39 patents are valid and enforceable, entered as a court order, does not bind third parties legally — but it signals to other generic filers (including Sun Pharmaceutical and Aurobindo, co-defendants in related actions) the scale of the patent thicket surrounding RINVOQ. Challengers typically face significant cost and litigation risk before any of these patents expire. AbbVie’s ability to replicate this outcome across parallel ANDAs would extend effective market exclusivity well beyond any single patent expiry.
Market exclusivity reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Global biopharmaceutical company — holder of 39 upadacitinib (RINVOQ) patentsSearch in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Indian generic pharmaceutical group (Hetero Labs/USA) seeking U.S. approval for generic RINVOQSearch in Eureka ↗ |
| Co-Defendant | Hoster Labs Private Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Christopher N. Sipes | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | David P. Frazier | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Erica N. Anderson | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Herman H. Yue | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicholas L. Evoy | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Yi Sun | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Giancarlo L. Scaccia | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Jonathan R. Wise | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kathryn E. Albanese | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Renee Mosley Delcollo | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Scott J. Bornstein | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Greenberg Traurig PA | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order is notable for its explicit judicial findings: the court does not merely dismiss the case but actively adjudges and decrees that ANDA No. 218859 was an act of infringement under § 271(e)(2)(A) and permanently enjoins the Hetero defendants. Because Hetero expressly admitted validity and infringement of all 39 patents and waived appeal, the order functions as a binding judgment — not merely a voluntary dismissal. For AbbVie, this creates a judicial record of infringement admission usable in enforcement proceedings. For Hetero, the without-prejudice carve-out on other products preserves limited optionality for future upadacitinib ANDA strategies.
US11976077B2 and 38 further patents — upadacitinib (RINVOQ) formulation and synthesis
The five listed patents — US11976077B2, US11993605B2, USRE047221E, US11993606B2, and US8962629B2 — represent a cross-section of AbbVie’s upadacitinib IP estate, covering compound chemistry, formulation, and extended-release delivery of a selective JAK1 inhibitor. USRE047221E is a reissued patent, signalling AbbVie’s active prosecution strategy to broaden or correct earlier claims. The portfolio spans application dates ranging from the mid-2010s through recent continuation filings, reflecting a deliberate lifecycle management approach designed to maintain exclusivity well beyond any single patent’s expiry.
For generic pharmaceutical companies and biosimilar developers, AbbVie’s 39-patent RINVOQ estate represents one of the most densely layered small-molecule drug portfolios in the JAK inhibitor space. The asserted patents cover not only the active moiety but formulation, dosing regimens, and synthesis routes — meaning a generic entrant cannot design around the compound patent alone. For competitors in the JAK/STAT pathway therapeutics market (rheumatoid arthritis, atopic dermatitis, ulcerative colitis), the consent order reinforces that challenging any subset of these patents without a coordinated multi-patent invalidity strategy is strategically hazardous.
Should you run an FTO against AbbVie’s upadacitinib patent portfolio?
Any company developing a JAK1 inhibitor, an extended-release tablet formulation of a JAK inhibitor, or a generic or biosimilar upadacitinib product for any indication should treat AbbVie’s RINVOQ portfolio as a mandatory FTO target. The 39-patent scope — spanning compound, formulation, synthesis, and dosage claims — means that clearance of the active ingredient patent alone is insufficient. R&D teams evaluating ANDA filings, novel JAK1 candidates, or alternative dosage forms should map the full patent family before committing to development spend.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map every patent in AbbVie’s upadacitinib family — including continuations, reissues, and term extensions — against a proposed product’s claims in minutes. Eureka cross-references ANDA status, litigation history, and patent expiry data to surface the patents most likely to be asserted, helping teams prioritise design-around or challenge strategies before filing costs escalate.
Run a freedom-to-operate analysis on US11976077B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman JAK inhibitor patent cases in Delaware District Court
Cases involving ANDA challenges to JAK inhibitor and small-molecule oral tablet patents litigated before the Delaware District Court under Hatch-Waxman.
What this case signals for the JAK inhibitor generics IP landscape
AbbVie’s 39-patent consent injunction sets a high-watermark for RINVOQ lifecycle defence and raises the stakes for every pending generic challenger.
A 39-patent ANDA suit is a deterrent architecture, not just litigation
Asserting 39 patents against a single ANDA forces any generic challenger to evaluate the litigation cost of challenging each patent independently. Hetero’s capitulation within 400 days — without trial — confirms that the portfolio breadth alone can deter commercialisation. IP teams at originator pharma companies should audit JAK inhibitor portfolios for similar layered coverage across synthesis, formulation, and dosing claims.
Consent orders with appeal waivers create durable exclusivity beyond patent expiry cliffs
By securing Hetero’s express waiver of appeal rights in a court order, AbbVie eliminated the uncertainty of an IPR or post-grant challenge from this defendant. Generic developers and their litigation counsel should factor consent-order dynamics into ANDA strategy — a defendant who signs a consent order with an appeal waiver cannot later file a covered business method or IPR petition on the same patents without risking contempt exposure.
AbbVie v Hetero — key questions answered
The Delaware District Court entered a consent stipulated order on 12 September 2025 permanently enjoining Hetero USA, Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hoster Labs Private Limited from manufacturing, selling, or importing generic upadacitinib ER tablets covered by ANDA No. 218859 for the life of all 39 asserted patents, absent an AbbVie licence. Hetero expressly admitted infringement and validity of all 39 patents and waived appeal rights.
AbbVie asserted 39 U.S. patents covering upadacitinib extended-release tablets, spanning compound chemistry, formulation, synthesis routes, and dosing regimens. The patents included USRE047221E (a reissued patent) and multiple recent continuation filings. Hetero admitted all 39 patents are valid, enforceable, and would be infringed by commercial sale of its ANDA products.
No. Sun Pharmaceutical Industries, Ltd. and Aurobindo Pharma Ltd. appear as co-defendants in related but separate actions. The consent order binds only the Hetero defendants and does not constitute a binding legal finding of validity or infringement as to any other party. However, Hetero’s withdrawal removes a potential co-challenger from coordinated invalidity efforts, which may increase the litigation burden on remaining defendants.
The order dismisses all claims, counterclaims, and defences other than the infringement admission without prejudice — meaning Hetero retains the right to litigate those issues in future. Specifically, paragraph 7 of the order preserves Hetero’s ability to challenge the 39 patents in any future action involving a upadacitinib product other than the specific ANDA 218859 formulation, giving Hetero limited strategic optionality for alternative product filings.
Upadacitinib is a selective JAK1 inhibitor marketed by AbbVie as RINVOQ, approved for rheumatoid arthritis, atopic dermatitis, ulcerative colitis, and other indications. RINVOQ is one of AbbVie’s highest-revenue products, making generic entry commercially significant. AbbVie has constructed a 39-patent estate covering compound, formulation, and method claims — a lifecycle management strategy designed to delay generic competition well beyond any single patent expiry.
PatSnap Eureka searches patents and litigation data to answer instantly.